ArticleActa pharmaceutica Sinica. B2025

Leveraging glypican-3 (GPC3)-mediated lysosome-targeting chimeras (GLTACs) for targeted membrane protein degradation.

Bin YuPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.